Renée Turzanski Fortner started at the Cancer Registry of Norway in 2021. Fortner is a cancer epidemiologist with a special interest in breast and gynecological cancer, underlying biological mechanisms linking risk factors and cancer, and early detection and cancer survival. Fortner leads research on lifestyle, reproductive, hormonal, inflammation and infection-related influences and cancer in large prospective cohorts in Europe and the United States, and in international consortia. Fortner holds a Ph.D. in reproductive epidemiology from the University of Massachusetts Amherst, and has been a postdoctoral fellow in cancer epidemiology at T.H. Chan Harvard School of Public Health, and Brigham and Women's Hospital/Harvard Medical School. She has been a European Commission Marie Skłodowska-Curie Fellow at the Section for Cancer Epidemiology at the German Cancer Research Centre (DKFZ), and has subsequently headed the Hormones and Cancer Group at the section.
Renée Turzanski Fortner, Ph.D., is a cancer epidemiologist with a special interest in breast and gynecological cancer, underlying biological mechanisms linking risk factors and cancer, and early detection and cancer survival. Fortner leads research on lifestyle, reproductive, hormonal, inflammation and infection-related influences and cancer in large prospective cohorts in Europe and the United States, and in international consortia. She is also part of the leadership of consortia for risk and early detection of ovarian cancer.
Fortner holds a Ph.D. in reproductive epidemiology from the University of Massachusetts Amherst, and has been a postdoctoral fellow in cancer epidemiology at T.H. Chan Harvard School of Public Health, and Brigham and Women's Hospital/Harvard Medical School. She has been a European Commission Marie Skłodowska-Curie Fellow at the Section for Cancer Epidemiology at the German Cancer Research Centre (DKFZ), and has subsequently headed the Hormones and Cancer Group at the section. She started at the Cancer Registry of Norway in 2021.
- JanusRNA - identification of early cancer biomarkers
- PREDICT Consortium - Prospective Early Detection Consortium for Ovarian Cancer.
- Circulating Oxysterols and Survival Following Breast Cancer: A Molecular Epidemiology Study
- Biological mechanisms underpinning associations between adult body fatness and postmenopausal breast, endometrial and ovarian cancers : A systematic review demonstration project
- Aspirin and NSAIDs and ovarian and endometrial cancer risk and survival
Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947-1964: The Nurses' Health Study II, a prospective cohort study. Burchardt NA, Shafrir AL, Kaaks R, Tworoger SS, Fortner RT. Eur J Epidemiol. 2020 Dec 17. doi: 10.1007/s10654-020-00705-5. Online ahead of print. PMID: 33331993
Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium. Fortner RT, Rice MS, Knutsen SF, Orlich MJ, Visvanathan K, Patel AV, Gaudet MM, Tjønneland A, Kvaskoff M, Kaaks R, Trichopolou A, Pala V, Onland-Moret NC, Gram IT, Amiano P, Idahl A, Allen NE, Weiderpass E, Poynter JN, Robien K, Giles GG, Milne RL, Setiawan VW, Merritt MA, van den Brandt PA, Zeleniuch-Jacquotte A, Arslan AA, O'Brien KM, Sandler DP, Wolk A, Håkansson N, Harris HR, Trabert B, Wentzensen N, Tworoger SS, Schouten LJ. Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):2010-2018. doi: 10.1158/1055-9965.EPI-20-0354. PMID: 32732252
Theoretical potential for endometrial cancer prevention through primary risk factor modification: Estimates from the EPIC cohort. Fortner RT, Hüsing A, Dossus L, Tjønneland A, Overvad K, Dahm CC, Arveux P, Fournier A, Kvaskoff M, Schulze MB, Bergmann M, Trichopoulou A, Karakatsani A, La Vecchia C, Masala G, Pala V, Mattiello A, Tumino R, Ricceri F, van Gils CH, Monninkhof EM, Bonet C, Quirós JR, Sanchez MJ, Rodríguez-Palacios DÁ, Gurrea AB, Amiano P, Allen NE, Travis RC, Gunter MJ, Viallon V, Weiderpass E, Riboli E, Kaaks R. Int J Cancer. 2020 Sep 1;147(5):1325-1333. doi: 10.1002/ijc.32901. Epub 2020 Feb 18. PMID: 3201173
Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort. Idahl A, Le Cornet C, González Maldonado S, Waterboer T, Bender N, Tjønneland A, Hansen L, Boutron-Ruault MC, Fournier A, Kvaskoff M, Boeing H, Trichopoulou A, Valanou E, Peppa E, Palli D, Agnoli C, Mattiello A, Tumino R, Sacerdote C, Onland-Moret NC, Gram IT, Weiderpass E, Quirós JR, Duell EJ, Sánchez MJ, Chirlaque MD, Barricarte A, Gil L, Brändstedt J, Riesbeck K, Lundin E, Khaw KT, Perez-Cornago A, Gunter MJ, Dossus L, Kaaks R, Fortner RT.Int J Cancer. 2020 Oct 15;147(8):2042-2052. doi: 10.1002/ijc.32999. Epub 2020 Apr 24.PMID: 32243586
Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort. Lu DL, Le Cornet C, Sookthai D, Johnson TS, Kaaks R, Fortner RT.J Natl Cancer Inst. 2019 Apr 1;111(4):365-371. doi: 10.1093/jnci/djy115.PMID: 30016454
Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies. Fortner RT, Terry KL, Bender N, Brenner N, Hufnagel K, Butt J, Waterboer T, Tworoger SS.Br J Cancer. 2019 Apr;120(8):855-860. doi: 10.1038/s41416-019-0422-9. Epub 2019 Mar 21.PMID: 30894687
